Takeda Pharmaceutical has entered into a major global collaboration with China’s Innovent Biologics, valued at up to $11.4 billion, to co-develop and commercialise next-generation cancer therapies worldwide, including in the United States. The partnership will focus on immuno-oncology and antibody-drug conjugate (ADC) treatments, led by Innovent’s key investigational assets IBI363 and IBI343, targeting solid tumours […]
Roche has received U.S. FDA approval for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adults with active lupus nephritis, used in combination with standard therapy. This approval marks a significant step forward in the management of this complex autoimmune disease, offering patients a new therapeutic option with a shorter 90-minute infusion time. Why This Milestone Matters […]